Eli Lilly headquarters located in Indianapolis, Indiana.

Although the GLP-1 drug Zepbound has been shown to be effective in promoting weight loss, availability and price have been barriers to more widespread use by patients.

In August, manufacturer Eli Lilly responded by offering Zepbound vials in 2.5 milligram and 5 milligram dosage strengths through its online LillyDirect pharmacy at a discount of 50% or more compared to the list price of other GLP-1 medicines for obesity. “Our goal is to break down barriers and provide patients with safe and effective options they can rely on,” said Patrik Jonsson, president of Lilly Cardiometabolic Health and Lilly USA.


NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2024 ALM Global, LLC. All Rights Reserved.